Marketing-authorisation holder · Ireland
Regeneron Ireland Designated Activity Company
19 medicines in 4 countries, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder · Ireland
19 medicines in 4 countries, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
19 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| LIBTAYOConcentrato per soluzione per infusione | Cemiplimab | Italy | Authorised | |
| Libtayo | Cemiplimab | EU (EMA) | Authorised | 2019 |
| Libtayo 350 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Cemiplimab | Netherlands | Authorised | 2019 |
| LIBTAYO 350 MG CONCENTRADO PARA SOLUCION PARA PERFUSION350 mg · Concentrado para solución para perfusión | Cemiplimab | Spain | Authorised | 2026 |
| LIBTAYO 350 MG CONCENTRADO PARA SOLUCION PARA PERFUSION350 mg · Concentrado para solución para perfusión | Cemiplimab | Spain | Marketed | 2019 |
| LYNOZYFICConcentrato per soluzione per infusione | Linvoseltamab | Italy | Authorised | |
| Lynozyfic | Linvoseltamab | EU (EMA) | Authorised | 2025 |
| LYNOZYFIC 200 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Linvoseltamab | Netherlands | Authorised | 2025 |
| LYNOZYFIC 200 MG CONCENTRADO PARA SOLUCION PARA PERFUSION200 mg · Concentrado para solución para perfusión | Linvoseltamab | Spain | Authorised | 2025 |
| LYNOZYFIC 5 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Linvoseltamab | Netherlands | Authorised | 2025 |
| LYNOZYFIC 5 MG CONCENTRADO PARA SOLUCION PARA PERFUSION5 mg · Concentrado para solución para perfusión | Linvoseltamab | Spain | Authorised | 2025 |
| ORDSPONOConcentrato per soluzione per infusione | Odronextamab | Italy | Authorised | |
| Ordspono | Odronextamab | EU (EMA) | Authorised | 2024 |
| Ordspono 2 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Odronextamab | Netherlands | Authorised | 2024 |
| ORDSPONO 2 MG CONCENTRADO PARA SOLUCION PARA PERFUSION2 mg · Concentrado para solución para perfusión | Odronextamab | Spain | Authorised | 2025 |
| Ordspono 320 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Odronextamab | Netherlands | Authorised | 2024 |
| ORDSPONO 320 MG CONCENTRADO PARA SOLUCION PARA PERFUSION320 mg · Concentrado para solución para perfusión | Odronextamab | Spain | Authorised | 2025 |
| Ordspono 80 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Odronextamab | Netherlands | Authorised | 2024 |
| ORDSPONO 80 MG CONCENTRADO PARA SOLUCION PARA PERFUSION80 mg · Concentrado para solución para perfusión | Odronextamab | Spain | Authorised | 2025 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 7 | 7 | 0 | CompaniesAll medicines |
| Netherlands | 6 | 6 | 0 | CompaniesAll medicines |
| European Union (EMA) | 3 | 3 | 0 | CompaniesAll medicines |
| Italy | 3 | 3 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.